Familial hypercholesterolemia: current treatment and advances in management

References

• Goldstein JL, Hobbs, HH, Brown MS. The metabolic and molecular bases of inherited disease 2863–2913 (2001).
   Google Scholar
• Pullinger CR, Hennessy LK, Chatterton J E et al. Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity. J. Clin. Invest.95, 1225–1234 (1995).
   PubMed Web of Science ®Google Scholar
• Fouchier SW, Kastelein JJ, Defesche JC. Update of the molecular basis of familial hypercholesterolemia in The Netherlands. Hum. Mutat.26, 550–556 (2005).
   PubMed Web of Science ®Google Scholar
• Defesche JC, Pricker KL, Hayden MR, van der Ende BE, Kastelein JJ. Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia. Arch. Intern. Med.153, 2349–2356 (1993).
   PubMedGoogle Scholar
• Miserez AR, Keller U. Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-1-h100 and familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol.15, 1719–1729 (1995).
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabes JP et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet.34, 154–156 (2003).
   PubMed Web of Science ®Google Scholar
• Allard D, Amsellem S, Abifadel M et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum. Mutat.26, 497 (2005).
   PubMedGoogle Scholar
• Zhang DW, Lagace TA, Garuti R et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem.282, 18602–18612 (2007).
   PubMed Web of Science ®Google Scholar
• Leitersdorf E, Tobin EJ, Davignon J, Hobbs HH. Common low-density lipoprotein receptor mutations in the French Canadian population. J. Clin. Invest.85, 1014–1023 (1990).
   PubMed Web of Science ®Google Scholar
• Williams RR, Hunt SC, Schumacher MC et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol.72, 171–176 (1993).
   PubMed Web of Science ®Google Scholar
• Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ303, 893–896 (1991).
   Google Scholar
• Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis142, 105–112 (1999).
   Google Scholar
• World Health Organisation, human genetics program: FH: Report of a WHO consultation, WHO/HGN/FH/CONS/98.7 (1997).
   Google Scholar
• Damgaard D, Larsen ML, Nissen PH et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis180, 155–160 (2005).
   PubMed Web of Science ®Google Scholar
• Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ321, 1497–1500 (2000).
   PubMed Web of Science ®Google Scholar
• Leren TP, Manshaus T, Skovholt U et al. Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. Semin. Vasc. Med.4, 75–85 (2004).
   PubMedGoogle Scholar
• Pocovi M, Civeira F, Alonso R, Mata P. Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semin. Vasc. Med.4, 67–74 (2004).
   PubMedGoogle Scholar
• Thorsson B, Sigurdsson G, Gudnason V. Systematic family screening for familial hypercholesterolemia in Iceland. Arterioscler. Thromb. Vasc. Biol.23, 335–338 (2003).
   PubMed Web of Science ®Google Scholar
• Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet357, 165–168 (2001).
   PubMed Web of Science ®Google Scholar
• Umans-Eckenhausen MA, Defesche JC, van Dam MJ, Kastelein JJ. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch. Intern. Med.163, 65–68 (2003).
   PubMedGoogle Scholar
• Marang-van de Mheen PJ, ten Asbroek AH, Bonneux L, Bonsel GJ, Klazinga NS. Cost-effectiveness of a family and DNA based screening program on familial hypercholesterolaemia in The Netherlands. Eur. Heart J.23, 1922–1930 (2002).
   PubMed Web of Science ®Google Scholar
• Gudnason V, Day IN, Humphries SE. Effect on plasma lipid levels of different classes of mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolemia. Arterioscler. Thromb.14, 1717–1722 (1994).
   PubMedGoogle Scholar
• Souverein OW, Defesche JC, Zwinderman AH, Kastelein JJ, Tanck MW. Influence of LDL-receptor mutation type on age at first cardiovascular event in patients with familial hypercholesterolaemia. Eur. Heart J.28, 299–304 (2007).
   PubMedGoogle Scholar
• Koeijvoets KC, Wiegman A, Rodenburg J, Defesche JC, Kastelein JJ, Sijbrands EJ. Effect of low-density lipoprotein receptor mutation on lipoproteins and cardiovascular disease risk: a parent-offspring study. Atherosclerosis180, 93–99 (2005).
   PubMed Web of Science ®Google Scholar
• Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation106, 3031–3036 (2002).
   PubMed Web of Science ®Google Scholar
• Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation79, 225–232 (1989).
   PubMed Web of Science ®Google Scholar
• Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet2, 1380–1382 (1969).
   PubMed Web of Science ®Google Scholar
• Gagne C, Moorjani S, Brun D, Toussaint M, Lupien PJ. Heterozygous familial hypercholesterolemia.Relationship between plasma lipids, lipoproteins, clinical manifestations and ischaemic heart disease in men and women. Atherosclerosis34, 13–24 (1979).
   PubMed Web of Science ®Google Scholar
• De Groot E, Hovingh GK, Wiegman A et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation109, III33–III38 (2004).
   PubMed Web of Science ®Google Scholar
• Wiegman A, de Groot E, Hutten BA et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet363, 369–370 (2004).
   PubMed Web of Science ®Google Scholar
• Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA256, 2835–2838 (1986).
   PubMed Web of Science ®Google Scholar
• Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis173, 55–68 (2004).
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation106, 3143–3421 (2002).
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110, 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Ma PT, Gil G, Sudhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc. Natl Acad. Sci. USA83, 8370–8374 (1986).
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ326, 1423 (2003).
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet366, 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet357, 577–581 (2001).
   PubMed Web of Science ®Google Scholar
• Arambepola C, Farmer AJ, Perera R, Neil HA. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: A systematic review and meta-analysis. Atherosclerosis (2006).
   PubMedGoogle Scholar
• Avis HJ, Vissers MN, Stein EA et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol.27, 1803–1810 (2007).
   PubMed Web of Science ®Google Scholar
• Rodenburg J, Vissers MN, Wiegman A et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation116, 664–668 (2007).
   PubMed Web of Science ®Google Scholar
• Kavey RE, Allada V, Daniels SR et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation114, 2710–2738 (2006).
   PubMed Web of Science ®Google Scholar
• Bliznakov EG. Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case – a modern Pandora’s box. Biomed. Pharmacother.56, 56–59 (2002).
   PubMed Web of Science ®Google Scholar
• Hiyoshi H, Yanagimachi M, Ito M et al. Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors. J. Lipid Res.41, 1136–1144 (2000).
   PubMed Web of Science ®Google Scholar
• Ugawa T, Kakuta H, Moritani H et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br. J. Pharmacol.131, 63–70 (2000).
   PubMed Web of Science ®Google Scholar
• Nicolosi RJ, Wilson TA, Krause BR. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters. Atherosclerosis137, 77–85 (1998).
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, L’Allier PL et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation110, 3372–3377 (2004).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Brewer HB et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med.354, 1253–1263 (2006).
   PubMed Web of Science ®Google Scholar
• Meuwese MC, Duivenvoorden R, Zwinderman AH et al. Effect of ACAT inhibition on carotid atherosclerosis in familial hypercholesterolemia. J. Clin. Lipidol. (XVI DALM Symposium NY 2007)1, 382–382 (2007).
   Google Scholar
• Bell TA III, Brown JM, Graham MJ, Lemonidis KM, Crooke RM, Rudel LL. Liver-specific inhibition of acyl-coenzyme a:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor-/- mice. Arterioscler. Thromb. Vasc. Biol.26, 1814–1820 (2006).
   PubMed Web of Science ®Google Scholar
• Whitfield AJ, Barrett PH, Robertson K, Havlat MF, van Bockxmeer FM, Burnett JR. Liver dysfunction and steatosis in familial hypobetalipoproteinemia. Clin. Chem.51, 266–269 (2005).
   PubMed Web of Science ®Google Scholar
• Jamil H, Gordon DA, Eustice DC et al. An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Proc. Natl Acad. Sci. USA93, 11991–11995 (1996).
   PubMed Web of Science ®Google Scholar
• Cuchel M, Bloedon LT, Szapary PO et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med.356, 148–156 (2007).
   PubMed Web of Science ®Google Scholar
• Aggarwal D, West KL, Zern TL, Shrestha S, Vergara-Jimenez M, Fernandez ML. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC. Cardiovasc. Disord.5, 30 (2005).
   PubMedGoogle Scholar
• Kastelein JJ, Wedel MK, Baker BF et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation114, 1729–1735 (2006).
   PubMed Web of Science ®Google Scholar
• Akdim F, Stroes ES, Kastelein JJ. Antisense apolipoprotein B therapy: where do we stand? Curr. Opin. Lipidol.18, 397–400 (2007).
   PubMed Web of Science ®Google Scholar
• Altmann SW, Davis HR Jr Zhu LJ et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science303, 1201–1204 (2004).
   PubMed Web of Science ®Google Scholar
• Sudhop T, Lutjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation106, 1943–1948 (2002).
   PubMed Web of Science ®Google Scholar
• Dujovne CA, Ettinger MP, McNeer JF et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol.90, 1092–1097 (2002).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation107, 2409–2415 (2003).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Denke MA, McBride PE et al. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial. Mayo Clin. Proc.81, 1177–1185 (2006).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEPATPIII goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc.80, 587–595 (2005).
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Sager PT, de Groot E, Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am. Heart J.149, 234–239 (2005).
   PubMed Web of Science ®Google Scholar
• Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin. Proc.78, 965–978 (2003).
   PubMed Web of Science ®Google Scholar
• Jakulj L, Vissers MN, Rodenburg J, Wiegman A, Trip MD, Kastelein JJ. Plant stanols do not restore endothelial function in pre-pubertal children with familial hypercholesterolemia despite reduction of low-density lipoprotein cholesterol levels. J. Pediatr.148, 495–500 (2006).
   PubMed Web of Science ®Google Scholar
• Jakulj L, Trip MD, Sudhop T, von Bergmann K, Kastelein JJ, Vissers MN. Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels. J. Lipid Res.46, 2692–2698 (2005).
   PubMed Web of Science ®Google Scholar
• Li H, Xu G, Shang Q, Pan L et al. Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7 α-hydroxylase. Metabolism53, 927–932 (2004).
   PubMed Web of Science ®Google Scholar
• Huff MW, Telford DE, Edwards JY et al. Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB. Arterioscler. Thromb. Vasc. Biol.22, 1884–1891 (2002).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Dillon MA, Gordon B et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med.159, 1893–1900 (1999).
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA251, 351–364 (1984).
   Google Scholar
• Insull W Jr, Toth P, Mullican W et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin. Proc.76, 971–982 (2001).
   PubMed Web of Science ®Google Scholar
• Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis158, 407–416 (2001).
   PubMed Web of Science ®Google Scholar
• Bays H, Rhyne J, Abby S, Lai YL, Jones M. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr. Med. Res. Opin.22, 2191–2200 (2006).
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med.357, 1301–1310 (2007).
   PubMed Web of Science ®Google Scholar
• Junyent M, Cofan M, Nunez I, Gilabert R, Zambon D, Ros E. Influence of HDL cholesterol on preclinical carotid atherosclerosis in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol.26, 1107–1113 (2006).
   PubMed Web of Science ®Google Scholar
• Neil HA, Seagroatt V, Betteridge DJ et al. Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart90, 1431–1437 (2004).
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation79, 8–15 (1989).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin.22, 2243–2250 (2006).
   PubMed Web of Science ®Google Scholar
• Birjmohun RS, Kastelein JJ, Poldermans D, Stroes ES, Hostalek U, Assmann G. Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. Curr. Med. Res. Opin.23, 1707–1713 (2007).
   PubMed Web of Science ®Google Scholar
• Cheng K, Wu TJ, Wu KK et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl Acad. Sci. USA103, 6682–6687 (2006).
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Smilde TJ, van Wissen S et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis173, 261–267 (2004).
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med.356, 1620–1630 (2007).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M et al. Effects of Torcetrapib in Patients at High Risk for Coronary Events. N. Engl. J. Med.357, 2109–2122 (2007).
   PubMed Web of Science ®Google Scholar
• Prospective Studies Collaborators Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet370, 1829–1839 (2007).
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc. Drugs Ther.19, 403–414 (2005).
   PubMed Web of Science ®Google Scholar
• Dubuc G, Chamberland A, Wassef H et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol.24, 1454–1459 (2004).
   PubMed Web of Science ®Google Scholar
• Rashid S, Curtis DE, Garuti R et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl Acad. Sci. USA102, 5374–5379 (2005).
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, Frank-Kamenetsky M, Zimmermann TS et al. RNAi therapeutics for the lowering of LDL cholesterol. J. Clin. Lipidol. (XVIDALMSymposium NY 2007)1, 378–378 (2007).
   Google Scholar